AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered according to package insert
Study NCT01440023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Placebo Cognitive Training
Description: Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
Study NCT02194231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
Study NCT00837031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
Study NCT00837031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
Study NCT00837577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to sitagliptin once daily for 12 weeks (double-blind period)
Study NCT00837577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20.
Study NCT00837577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Description: All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study.
Study NCT02345863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated.
Study NCT02345863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg
Study NCT02345863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily
Study NCT04676919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phonophoresis therapy with pulsed mode ultrasound
Description: phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
Study NCT04676919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phonophoresis therapy with continuous mode ultrasound
Description: phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
Study NCT04676919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: sham ultrasound therapy, five days a week for three weeks
Study NCT02156466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study NCT02156466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study NCT02156466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study NCT02156466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010841
Description: MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study NCT02156466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study NCT00515385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Study NCT00515385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MGAWN1
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered according to package insert
Study NCT02348216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered according to package insert
Study NCT00525317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
Description: 120 mg x 3 or placebo
Study NCT00525317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
Description: 120 mg x 3 or placebo
Study NCT03663075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group information (GI)
Description: The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
Study NCT03663075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured person-centered support (PCS)
Description: The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
Study NCT00918294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt
Description: The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
Study NCT03871387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Group
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Study NCT03871387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Study NCT00125216 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Response Elaboration Training
Description: Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
Study NCT03286491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Further cardiac imaging
Description: Study patients will be reviewed whether they will have coronary interventions in 30 days
Study NCT01679535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and hygiene education
Description: Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
Study NCT02740348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ZocDoc Assistance
Description: Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
Study NCT02740348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ZocDoc Information
Description: Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
Study NCT02417246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brand name metoprolol ER
Description: This medication will be taken for 7 to 28 days
Study NCT00515385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Single IV dose
Study NCT02417246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic A
Description: This medication will be taken for 7 days
Study NCT02417246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic B
Description: This medication will be taken for 7 days
Study NCT04483479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Investigational Treatment ENT-01
Description: ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
Study NCT00759109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
Study NCT00759109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation (no treatment)
Description: No treatment was given to participants enrolled in the control arm (Arm B).
Study NCT01889420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle.
Study NCT00515385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose
Study NCT01186952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
Study NCT01186952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention and structured exercise training program
Description: Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
Study NCT02579369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells
Description: Dressing for Dystrophic Epidermolysis Bullosa wound.
Study NCT02579369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethene Film
Description: Dressing for Dystrophic Epidermolysis Bullosa wound.
Study NCT01532037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy based self help
Description: Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
Study NCT01532037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Usual care from healthcare professionals with regard to patients symptoms of fatigue
Study NCT04274088 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Phacoemulsification surgery
Study NCT02380066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Placebo
Study NCT00365859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
Study NCT02380066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anyu Peibo
Description: Placebo
Study NCT03708744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B: M207 3.8 mg, 30 min, thigh
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Study NCT03708744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Study NCT02232529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study NCT02232529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05582863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise intervention
Description: The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 1 mg BID capsules
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2 mg BID capsules
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 5 mg BID capsules
Study NCT03708744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Study NCT03708744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 10 mg BID capsules
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID capsules
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Study NCT04592198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride Buccal Film 0.25 Mg
Description: Dose equal to the iv control
Study NCT04592198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride Buccal Film 0.5 Mg
Description: Dose twice that of iv control
Study NCT04592198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
Description: iv control
Study NCT00667498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study NCT00406029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study NCT00667498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Study NCT00730470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (AMG888)
Description: IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
Study NCT03708744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan
Study NCT03805698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma (PRP)
Description: The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
Study NCT03805698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arthroscopic Debridement
Description: Standard arthroscopic debridement. No PRP injection.
Study NCT01000415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Description: Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
Study NCT02765347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
Study NCT02765347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: For arm 2, just accept insulin for 24 weeks